002099 海翔药业
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.179-6.147-7.1721.4401.592
总资产报酬率 ROA (%)0.123-4.411-5.2791.0721.253
投入资产回报率 ROIC (%)0.136-4.895-5.8431.1771.361

边际利润分析
销售毛利率 (%)25.14526.73814.02726.63637.243
营业利润率 (%)3.289-17.341-21.3754.0464.912
息税前利润/营业总收入 (%)0.751-20.477-22.908-0.0625.764
净利润/营业总收入 (%)1.709-17.224-19.4113.1833.778

收益指标分析
经营活动净收益/利润总额(%)156.791-23.51734.630226.02495.789
价值变动净收益/利润总额(%)38.8702.28825.229-41.9997.966
营业外收支净额/利润总额(%)-26.9800.2190.425-8.5270.804

偿债能力分析
流动比率 (X)1.3221.2971.4531.6471.984
速动比率 (X)0.9850.9381.0651.0881.460
资产负债率 (%)32.30431.17225.51027.26323.770
带息债务/全部投入资本 (%)23.68321.95615.74317.30814.636
股东权益/带息债务 (%)316.683348.943524.765464.876567.126
股东权益/负债合计 (%)209.895221.110292.245266.936320.775
利息保障倍数 (X)-0.4096.60915.8870.0167.090

营运能力分析
应收账款周转天数 (天)81.13978.31376.54465.76864.824
存货周转天数 (天)197.168190.371173.972182.408188.772